Dr. Ariel Graff, MD, PhD
Claim this profileCentre for Addiction and Mental Health
Studies Schizophrenia
Studies Anosognosia
7 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials Ariel Graff, MD, PhD is currently running
Psilocybin
for Mild Cognitive Impairment
The goal of this clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brain will be higher following the ingestion of psilocybin in comparison to placebo, and that increases in SVD will be associated with improvements in cognition. 60 participants (30 with aMCI, and 30 sex and age matched healthy volunteers) will: * Be randomized to receive either: 1. Two 25 mg macrodoses of psilocybin separated by 1 week. 2. Two placebo doses separated by 1 week. * Receive a baseline 18F-SynVesT-1 PET scan, clinical, and neuropsychological assessments. * Receive a 18F-SynVesT-1 PET scan one week after the last dose of treatment. * Receive a third PET scan at any time within 4 weeks of the screening visit to quantify tauopathy with the \[18F\]T807 radiotracer. * Receive clinical and neuropsychological testing 1, 4, and 12 weeks after the last treatment. Researchers will compare placebo vs. experimental groups to see if psilocybin will increase SVD, and if increases in SVD are associated with cognitive improvements.
Recruiting0 awards Phase 210 criteria
tDCS
for Schizophrenia
This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia. Synaptic density levels will be measured using a novel positron emission tomography (PET) radiotracer \[18F\]SDM-8, which is currently the best-in-class method to quantify synaptic density in humans. This will be a companion study to a parent study by our group examining the effects of tDCS on treatment adherence in schizophrenia (REB #103-2018).
Recruiting1 award N/A5 criteria
More about Ariel Graff, MD, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ariel Graff, MD, PhD has experience with
- TDCS
- Active TDCS
- Sham TDCS
- MRI And PET Scans
- [18F]SDM-8
- Investigational Brainstem Neuromodulation Device
Breakdown of trials Ariel Graff, MD, PhD has run
Schizophrenia
Psychotic Episodes
Medication Adherence
Psychosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ariel Graff, MD, PhD specialize in?
Ariel Graff, MD, PhD focuses on Schizophrenia and Anosognosia. In particular, much of their work with Schizophrenia has involved treating patients, or patients who are undergoing treatment.
Is Ariel Graff, MD, PhD currently recruiting for clinical trials?
Yes, Ariel Graff, MD, PhD is currently recruiting for 3 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Ariel Graff, MD, PhD has studied deeply?
Yes, Ariel Graff, MD, PhD has studied treatments such as TDCS, Active TDCS, Sham TDCS.
What is the best way to schedule an appointment with Ariel Graff, MD, PhD?
Apply for one of the trials that Ariel Graff, MD, PhD is conducting.
What is the office address of Ariel Graff, MD, PhD?
The office of Ariel Graff, MD, PhD is located at: Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8 Canada. This is the address for their practice at the Centre for Addiction and Mental Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.